But the application of ibrutinib, a drug that targets IL-2 inducible kinase (which is highly expressed in melanoma), did not deliver any clinical benefits in patients with metastatic melanoma whose PD-1 treatment was failed [49]. Here, PDCD1 is linked to metastatic melanoma.